ACE and benign prostatic hyperplasia: Using ganglion blockade with prior angiotensin-converting-enzyme (ACE) inhibitor pretreatment, the SNS contribution to BP was 1.7-fold greater in BPH/2 mice compared with BPN/3 mice during both light (inactive) and dark (active) periods (Jackson et al., 2013).